Osaic Holdings’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,006
| Closed | -$40.4K | – | 8091 |
|
|
2026
Q1 | $40.4K | Sell |
2,006
-19,931
| -91% | -$321K | ﹤0.01% | 5374 |
|
|
2025
Q4 | $354K | Sell |
21,937
-1,424
| -6% | -$18.9K | ﹤0.01% | 3645 |
|
|
2025
Q3 | $285K | Buy |
23,361
+1,446
| +7% | +$20K | ﹤0.01% | 3916 |
|
|
2025
Q2 | $248K | Buy |
+21,915
| New | +$268K | ﹤0.01% | 3760 |
|
|
2025
Q1 | – | Sell |
-20,804
| Closed | -$176K | – | 7588 |
|
|
2024
Q4 | $176K | Buy |
20,804
+144
| +0.7% | +$1.49K | ﹤0.01% | 3713 |
|
|
2024
Q3 | $239K | Sell |
20,660
-720
| -3% | -$9.06K | ﹤0.01% | 3506 |
|
|
2024
Q2 | $252K | Buy |
+21,380
| New | +$250K | ﹤0.01% | 3351 |
|
|
2022
Q3 | – | Sell |
-100
| Closed | -$1K | – | 7389 |
|
|
2022
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 7096 |
|
|
2022
Q1 | $1K | Hold |
100
| – | – | ﹤0.01% | 7063 |
|
|
2021
Q4 | $1K | Hold |
100
| – | – | ﹤0.01% | 7200 |
|
|
2021
Q3 | $2K | Hold |
100
| – | – | ﹤0.01% | 6864 |
|
|
2021
Q2 | $2K | Hold |
100
| – | – | ﹤0.01% | 6715 |
|
|
2021
Q1 | $3K | Buy |
+100
| New | +$2.63K | ﹤0.01% | 6371 |
|
Other funds holding KALV
Osaic Holdings's KALV Position: Q2 2026 in Review
Osaic Holdings sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,006 shares — an estimated $40.4K sold.
Osaic Holdings first reported a position in KALV in Q1 2021 and held it in 13 quarters. The position peaked at $354K in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Osaic Holdings reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Osaic Holdings sold 2,006 KalVista Pharmaceuticals shares in Q2 2026, an estimated $40.4K.
- Osaic Holdings first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 13 quarters.
- Osaic Holdings's KalVista Pharmaceuticals position peaked at $354K in Q4 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.